Paper · 28070720

Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study.

Saka H and 11 others. Invest New Drugs, 2017. Cited by 54 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study. Papers, record 28070720. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28070720

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study.; PubMed
Journal: Invest New Drugs; PubMed
Year: 2017; PubMed
Publication types: Clinical Trial, Phase I, Journal Article, Multicenter Study; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/28070720/; PubMed
DOI: https://doi.org/10.1007/s10637-016-0416-x; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC5502072/; PubMed
The journal: https://conductscience.org/library/journal-index/8309330; PubMed
Citations, by iCite: 54; iCite
Relative citation ratio, by iCite: 1.74; iCite
Revised in PubMed: 2024-06-01; PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Saka H	Hideo
2	Kitagawa C	Chiyoe
3	Kogure Y	Yoshihito
4	Takahashi Y	Yasuo
5	Fujikawa K	Koshi
6	Sagawa T	Tamotsu
7	Iwasa S	Satoru
8	Takahashi N	Naoki
9	Fukao T	Taro
10	Tchinou C	Catherine

1 to 10 of 12Source PubMed

See all 12 authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Antineoplastic Agents	Major topic
Benzamides	Major topic
Neoplasms	Major topic
Piperazines	Major topic
Pyrazoles	Major topic
Receptors, Fibroblast Growth Factor	Major topic
Adult
Aged
Asian People
Female
Half-Life
Humans
Male
Middle Aged
Treatment Outcome

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

Trial	Title	The trial lists it as	Named in the paper's record
NCT01213160	Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient	Derived from the trial	Yes

Source ClinicalTrials.gov

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References40

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	18,650,514	Sorafenib in advanced hepatocellular carcinoma.	N Engl J Med	2008	https://conductscience.org/library/papers/18650514	PubMed
2	26,590,673	Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.	Lancet Oncol	2016	https://conductscience.org/library/papers/26590673	PubMed
3	18,552,176	Drug-sensitive FGFR2 mutations in endometrial carcinoma.	Proc Natl Acad Sci U S A	2008	https://conductscience.org/library/papers/18552176	PubMed
4	16,894,390	Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy.	Nat Clin Pract Oncol	2006	https://conductscience.org/library/papers/16894390	PubMed
5	25,576,915	Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer.	Oncotarget	2015	https://conductscience.org/library/papers/25576915	PubMed
6	9,331,099	Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups.	Cancer Res	1997	https://conductscience.org/library/papers/9331099	PubMed
7	17,215,529	Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.	N Engl J Med	2007	https://conductscience.org/library/papers/17215529	PubMed
8	24,180,494	A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.	N Engl J Med	2013	https://conductscience.org/library/papers/24180494	PubMed
9	19,809,159	Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.	J Clin Invest	2009	https://conductscience.org/library/papers/19809159	PubMed
10	23,493,349	FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.	Clin Cancer Res	2013	https://conductscience.org/library/papers/23493349	PubMed

1 to 10 of 40

See all 40 references

Cited by37

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 54 citations.

PMID	Title	Journal	Year	In Papers	Source
42,446,762	Rewiring cancer cell fate toward vasculogenic mimicry: from classical to unconventional processes.	Cancer Metastasis Rev	2026	https://conductscience.org/library/papers/42446762	PubMed
41,328,353	FGF19 in Solid Tumors: Molecular Mechanisms, Metabolic Reprogramming, and Emerging Therapeutic Opportunities.	Theranostics	2026	https://conductscience.org/library/papers/41328353	PubMed
40,319,089	Harnessing the FGFR2/NF2/YAP signaling-dependent necroptosis to develop an FGFR2/IL-8 dual blockade therapeutic strategy.	Nat Commun	2025	https://conductscience.org/library/papers/40319089	PubMed
40,283,927	MicroRNAs as Sensitizers of Tyrosine Kinase Inhibitor Resistance in Cancer: Small Molecule Partnerships.	Pharmaceuticals (Basel)	2025	https://conductscience.org/library/papers/40283927	PubMed
39,621,133	FGF receptor kinase inhibitors exhibit broad antiviral activity by targeting Src family kinases.	Cell Mol Life Sci	2024	https://conductscience.org/library/papers/39621133	PubMed
39,462,221	Tasurgratinib in patients with cholangiocarcinoma or gastric cancer: Expansion part of the first-in-human phase I study.	Cancer Sci	2025	https://conductscience.org/library/papers/39462221	PubMed
39,199,681	Exploring the Horizon: Anti-Fibroblast Growth Factor Receptor Therapy in Pancreatic Cancer with Aberrant Fibroblast Growth Factor Receptor Expression-A Scoping Review.	Cancers (Basel)	2024	https://conductscience.org/library/papers/39199681	PubMed
38,916,962	FGF receptors mediate cellular senescence in the cystic fibrosis airway epithelium.	JCI Insight	2024	https://conductscience.org/library/papers/38916962	PubMed
38,638,441	Fibroblast growth factor receptor inhibitors mitigate the neuropathogenicity of Borrelia burgdorferi or its remnants ex vivo.	Front Immunol	2024	https://conductscience.org/library/papers/38638441	PubMed
37,889,382	Pharmacokinetics, pharmacodynamics and efficacy of pemigatinib (a selective inhibitor of fibroblast growth factor receptor 1-3) monotherapy in Chinese patients with advanced solid tumors: a phase i clinical trial.	Invest New Drugs	2023	https://conductscience.org/library/papers/37889382	PubMed

1 to 10 of 37

See all 37 cited by

Genes11

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes	Source
CMPK1	51,727	PubTator's text mining	https://conductscience.org/library/genes/51727	NCBI Gene
F3	2,152	PubTator's text mining	https://conductscience.org/library/genes/2152	NCBI Gene
FGF2	2,247	PubTator's text mining	https://conductscience.org/library/genes/2247	NCBI Gene
FGF23	8,074	PubTator's text mining	https://conductscience.org/library/genes/8074	NCBI Gene
FGFR1	2,260	PubTator's text mining	https://conductscience.org/library/genes/2260	NCBI Gene
FGFR2	2,263	PubTator's text mining	https://conductscience.org/library/genes/2263	NCBI Gene
FGFR3	2,261	PubTator's text mining	https://conductscience.org/library/genes/2261	NCBI Gene
FGFRL1	53,834	PubTator's text mining	https://conductscience.org/library/genes/53834	NCBI Gene
KDR	3,791	PubTator's text mining	https://conductscience.org/library/genes/3791	NCBI Gene
TXK	7,294	PubTator's text mining	https://conductscience.org/library/genes/7294	NCBI Gene

1 to 10 of 11

See all 11 genes

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

Drug	ChEMBL ID	The trials list it as	Trials	In Drugs and targets
FEXAGRATINIB	CHEMBL3348846	Derived from the trial	1	https://conductscience.org/library/drugs/CHEMBL3348846

Source ChEMBL

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28070720

GET https://conductscience.org/api/papers/v1/28070720/references?page=2

API reference For AI assistants